ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologicals"

  • Abstract Number: 0308 • ACR Convergence 2022

    Risankizumab (RZB) Demonstrates Long-Term Efficacy Across Subgroups in Patients with Active Psoriatic Arthritis (PsA): A Post Hoc, Integrated Analysis from the Phase 3 (KEEPsAKE 1 and KEEPsAKE 2) Studies

    Joseph Merola1, Kristina Callis-Duffin2, Byron Padilla3, Cuiyong Yue4, Huzefa Photowala4, Blair Kaplan4 and Iain B McInnes5, 1Harvard Medical School, Brigham and Women's Hospital, Boston, MA, 2University of Utah, Salt Lake City, UT, 3AbbVie, Inc., Waukegan, IL, 4AbbVie, Inc., North Chicago, IL, 5Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom

    Background/Purpose: Risankizumab (RZB), a fully humanized IgG1 monoclonal antibody inhibitor of IL-23, is a therapeutic agent approved for the treatment of active psoriatic arthritis (PsA)…
  • Abstract Number: 0414 • ACR Convergence 2022

    Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis with Intolerance to And/or Lack of Efficacy of Prior Biologic Therapy: A Subgroup Analysis

    Xenofon Baraliakos1, Fabiana Ganz2, Hideto Kameda3, Jessica Walsh4, Manish Jain5, Kristin D’Silva6, Peter Wung6, Xianwei Bu6, Jayne Stigler6 and Désirée van der Heijde7, 1Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 2AbbVie, Inc., Luzern, Switzerland, 3Toho University, Tokyo, Japan, 4University of Utah, Salt Lake City, UT, 5Great Lakes Clinical Trials, Chicago, IL, 6AbbVie, Inc., North Chicago, IL, 7Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands

    Background/Purpose: Upadacitinib (UPA), an oral Janus kinase inhibitor, has been evaluated in the treatment of AS both in patients (pts) naïve to biologic DMARDs (bDMARDs)1…
  • Abstract Number: 0595 • ACR Convergence 2022

    Validation of Urotensin-2 mRNA Expression as Marker for Tocilizumab Non-Response in Early Rheumatoid Arthritis

    Janani Sundaresan1, Ittai B. Muller1, Marry Lin1, Floris P.J.G. Lafeber2, Paco Welsing2, Maurits C.F.J. De Rotte3, Maja Bulatovic-Calasan4, Conny van der Laken5, Robert De Jonge6 and Gerrit Jansen5, 1Department of Clinical Chemistry, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, 2Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Department of Clinical Chemistry, Amsterdam University Medical Centers – location AMC, Amsterdam, Netherlands, 4Department of Clinical Chemistry, Amsterdam University Medical Centers – location VUmc, Amsterdam, The Netherlands; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 5Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, 6Department of Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam, Netherlands

    Background/Purpose: Tocilizumab (TCZ), a biologic Disease Modifying Anti-Rheumatic Drug, elicits an immune-modulating effect by binding to the interleukin 6 receptor and inhibiting downstream signaling. Despite…
  • Abstract Number: 0812 • ACR Convergence 2022

    3-years Safety and Efficacy Outcomes of Canakinumab Treatment in Cryopyrin-associated Periodic Syndromes (CAPS) – Data from the RELIANCE Registry

    Jasmin B. Kuemmerle-Deschner1, Birgit Kortus-Goetze2, Prasad T. Oommen3, Ales Janda4, Juergen Rech5, Catharina Schuetz6, Tilmann Kallinich7, Frank Weller-Heinemann8, Gerd Horneff9, Ivan Foeldvari10, Florian Meier11, Michael Borte12, Tobias Krickau13, Julia Weber-Arden14 and Norbert Blank15, 1Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tübingen, Tübingen, Germany, 2Division of Nephrology, University of Marburg, Marburg, Germany, 3Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, 4Department of Pediatrics, University Hospital Ulm, Ulm, Germany, 5University Clinic Erlangen, Erlangen, Germany, 6Pediatrics, Medizinische Fakultaet Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany, 7Charité - Universitätsmedizin Berlin, Nuremberg, Germany, 8Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, 9Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, 10Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, 11Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt, Germany, 12ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Sachsen, Germany, 13Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Pediatrics, Erlangen, Germany, 14Novartis Pharma GmbH, Nuernberg, Germany, 15Rheumatology, University Hospital Heidelberg, Heidelberg, Germany

    Background/Purpose: Cryopyrin-associated periodic syndromes (CAPS) are monogenic autoinflammatory diseases with severe systemic inflammation. The IL-1β inhibitor canakinumab (CAN) leads to a rapid remission of CAPS…
  • Abstract Number: 0978 • ACR Convergence 2022

    Belimumab After Rituximab Targets IgA2 Anti-dsDNA Antibody Production and Shifts Repopulating B-cells Towards an Anergic, Non-pathogenic Phenotype in Systemic Lupus Erythematosus

    Muhammad Shipa1, liliana ribeiro santos2, Dao X Nguyen1, Andrew Embleton-Thirsk1, Mariea parvaz1, David Isenberg1, Caroline Gordon3 and Michael Ehrenstein1, 1University College London, London, United Kingdom, 2University College London, London, 3Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom

    Background/Purpose: The results from the BEAT-lupus trial comparing belimumab vs placebo, both after rituximab in systemic lupus erythematosus (SLE) have recently been reported (1). We…
  • Abstract Number: 1159 • ACR Convergence 2022

    Uveitis in Psoriatic Arthritis: Study of 406 Patients in a Single University Center

    Ana De Vicente-Delmás1, Lara Sánchez-Bilbao2, Vanesa Calvo Río3, David Martínez-López2, Alba Herrero-Morant4, Eva Galíndez-Agirregoikoa5, Nuria Barroso-García6, Natalia Palmou-Fontana2, Miguel Ángel González-Gay7 and Ricardo Blanco8, 1Hospital General Santa María del Puerto, Cádiz, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Valdecilla Hospital, Santander, Spain, 4Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, 5Basurto University Hospital, Bilbao, Spain, 6Hospital Universitario Puerta del Mar, Cádiz, Spain, Cádiz, Spain, 7Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 8Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: The manifestations of uveitis are well-established in Axial Spondyloarthritis (ax-SpA), but not in Psoriatic Arthritis (PsA). We aimed to assess, in a large unselected…
  • Abstract Number: 1430 • ACR Convergence 2022

    Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis

    Cristiano Moura1, Luck Lukusa1, Laura Yan1, Walter P Maksymowych2, Denis Choquette3, Gilles Boire4 and Sasha Bernatsky1, 1Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 2Department of Medicine, University of Alberta, Edmonton, AB, Canada, 3Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, 4Universite de Sherbrooke, Sherbrooke, QC, Canada

    Background/Purpose: The first biosimilar etanercept (ETA-B) was approved in Canada in 2016, but real-world data comparing the effectiveness of ETA-B versus its equivalent originator (ETA-O)…
  • Abstract Number: 1795 • ACR Convergence 2022

    Therapeutic Strategies for Patients with Chronic Manifestations of Calcium Pyrophosphate Deposition Disease

    Julien Damart1, Silvia Sirotti2, Mariano Andrès3, Edoardo Cipolletta4, Georgios Filippou5, Davide Carboni6, Emilio Filippucci7, Pilar Diez8, Abhishek Abhishek9, Augustin Latourte10, Hang-Korng Ea11, Sebastien Ottaviani12, Jean-Guillaume Letarouilly13, Renaud Desbarbieux14, Sahara Graf1, Laurène Norberciak1, Pascal Richette15 and Tristan Pascart16, 1Hôpital Saint-Philibert, Lomme, France, 2Università degli Studi di Milano, Milano, Italy, 3Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, 4Polytechnic University of Marche, Ancona, Italy, 5Rheumatology Department, Luigi Sacco University Hospital, Siena, Italy, 6Luigi Sacco University, Milano, Italy, 7Polytechnic University of Marche, Rheumatology Unit, Department of Clinical and Molecular Sciences, "Carlo Urbani" Hospital, Jesi, Italy, 8Alicante University, Alicante, Spain, 9University of Nottingham, Nottingham, United Kingdom, 10Université de Paris, Paris, France, 11Lariboisière Hospital, Paris, France, 12Hopital Bichat-Claude Bernard, Paris, France, 13CHU Lille, Lille, France, 14Ch Boulogne-sur-Mer, Boulogne-sur-Mer, France, 15Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, 16Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France

    Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease lacks recommendations on treatment strategies. This study reports on treatment modalities used in European tertiary hospitals for the management…
  • Abstract Number: 2110 • ACR Convergence 2022

    Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population

    Laure Gossec1, Mohamed Sharaf2, Elke Theander3, Marlies Neuhold4, Paul Bergmans5, May Shawi6, Michelle Perate7, Christine Contré8 and Laura Coates9, 1Sorbonne Université, Paris, France, 2Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, 3Formerly at Janssen Scientific Affairs, LLC, Solna, Sweden, 4Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, 5Formerly at Janssen, Breda, Netherlands, 6Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 7Janssen Scientific Affairs, LLC, Horsham, PA, 8Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, 9Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: The Phase 3b COSMOS study (NCT03796858) demonstrated the efficacy and safety of guselkumab (GUS), an IL-23 p19 subunit inhibitor, in patients (pts) with psoriatic…
  • Abstract Number: 2192 • ACR Convergence 2022

    Serious Infections in Offspring Exposed During Late Pregnancy to Tumour Necrosis Factor Inhibitors with High versus Low Placental Transfer Ability

    Leah K. Flatman1, Yvan St. Pierre2, Isabelle Malhamé3, Olga Basso1, Anick Berard4, Sasha Bernatsky2 and Evelyne Vinet3, 1McGill University, Montréal, QC, Canada, 2Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 3McGill University Health Centre, Montréal, QC, Canada, 4University of Montreal, Montréal, QC, Canada

    Background/Purpose: During pregnancy, best practice guidelines suggest discontinuing tumour necrosis factor inhibitors (TNFi) with high placental transfer before or during the third trimester if the…
  • Abstract Number: L07 • ACR Convergence 2021

    Depletion of KLRG1+ T Cells in a First-in-human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM)

    Niti Goel1, Dulce Soler-Ferran2, Monette Coutreau2, Jorge Escobar3, Kate Courtemanche2, Merrilee Needham4 and Steven Greenberg5, 1Abcuro, Inc.; Duke University, Durham, NC, 2Abcuro, Inc., Newton, MA, 3Abcuro, Inc., Hayward, CA, 4Perron Institute, Murdoch University, Perth, Australia, 5Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Inclusion body myositis (IBM), a relentlessly progressive autoimmune skeletal muscle disease, has no effective available pharmacological therapy. A prominent feature of IBM on microscopy…
  • Abstract Number: L12 • ACR Convergence 2021

    Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23 Inhibition in Active PsA: Data from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial on Arthritis, Dactylitis, Enthesitis, Psoriasis, QoL and Function

    Michaela Koehm1, Tanja Rossmanith2, Ann Christina Foldenauer2, Eva Herrmann3, Herbert Kellner4, Uta Kiltz5, Jürgen Rech6, Gerd Burmester7, David Kofler8, Jan Brandt-Jürgens9, Christin Jonetzko10, Harald Burkhardt1 and Frank Behrens1, 1Rheumatology Goethe-University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, 2Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, 3Institute for Biostatistics and Mathematical Modeling, Goethe-Universität Frankfurt, Frankfurt, Germany, 4Praxis Prof. Dr. Kellner, München, Germany, 5Rheumazentrum Ruhrgebiet, Herne, Germany, 6Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054,, Erlangen, Germany, 7Charite Universitaetsmedizin Berlin, Germany and DRFZ, Berlin, Germany, 8Universitätsklinikum Köln, Med. Klinik I f. Innere Medizin Immunologische Ambulanz, Köln, Germany, 9Rheumatologische Schwerpunktpraxis im Ärztehaus am Walter-Schreiber-Platz, Berlin, Germany, 10Fraunhofer Insitute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany

    Background/Purpose: Methotrexate (MTX) is often used as first-line DMARD-therapy in active psoriatic arthritis (PsA). Randomized clinical trials usually require treatment failure or intolerance of csDMARD/MTX…
  • Abstract Number: L18 • ACR Convergence 2021

    Humoral and Cellular Immune Responses to a Second Dose of COVID-19 Vaccine BNT162b2 in People Receiving Methotrexate or Targeted Immunosuppression: A Cohort Study

    Satveer K Mahil1, Katie Bechman2, Antony Raharja1, Clara Domingo-Vila3, David Baudry1, Matt Brown2, Andrew Cope2, Tejus Dasandi1, Hataf Khan4, Thomas Lechmere4, Michael Malim4, Freya Meynell1, Emily Pollock3, Kamila Sychowska3, Jonathan Barker1, Sam Norton5, James Galloway2, Katie Doores4, Timothy Tree3 and Catherine Smith1, 1St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London, 2Centre for Rheumatic Diseases, King's College London, London, 3Department of Immunobiology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom, 4Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom, 5Psychology Department, Institute for Psychiatry Psychology & Neuroscience, King’s College London, London

    Background/Purpose: COVID-19 vaccines have robust immunogenicity in the general population. Data on individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains limited. Our cohort…
  • Abstract Number: L19 • ACR Convergence 2021

    Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial

    Nils Venhoff1, Wolfgang Schmidt2, Raoul Bergner3, Jürgen Rech4, Leonore Unger5, Hans-Peter Tony6, Meryl Mendelson7, Christian Sieder8, Meron Maricos8 and Jens Thiel9, 1Department of Rheumatology and Clinical Immunology, Vasculitis Center Freiburg, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany, 2Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Lindenberger Weg 19, 13125 Berlin, Germany, Berlin, Germany, 3Medizinische Klinik A, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany, 4Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054,, Erlangen, Germany, 5Medical Department 1, Städtisches Klinikum Dresden, Dresden, Germany, 6Department of Medicine 2, Rheumatology and Clinical Immunology Oberduerrbachertstr. 697080, Wuerzburg, Germany, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Novartis Pharma GmbH, Nuremberg, Germany, 9Department of Rheumatology and Clinical Immunology, Vasculitis Center Freiburg, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany; Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

    Background/Purpose: Little is known about glucocorticoid-sparing agents in giant cell arteritis (GCA) except for IL-6 inhibition. Secukinumab (SEC) has shown significant improvements in the signs…
  • Abstract Number: 0014 • ACR Convergence 2021

    Low Baseline Expression of Pyruvate Kinase and Succinate Dehydrogenase Genes in the Peripheral Blood of Rheumatoid Arthritis Patients Treated with Tofacitinib Is Associated with Clinical Remission at the End of Follow-up

    Elena Tchetina1, Azamat Satybaldyev2, Galina Markova1 and Alexander Lila2, 1Nasonova Research Institute of Rheumatology, Moscow, Russia, 2V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology, which is characterized by erosive arthritis and systemic inflammation. Tofacitinib (TFCN) is a Janus…
  • « Previous Page
  • 1
  • …
  • 47
  • 48
  • 49
  • 50
  • 51
  • …
  • 67
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology